Sorafenib, a multityrosine
kinase inhibitor, is a standard treatment for advanced
hepatocellular carcinoma (HCC), but the clinical response to
sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immune evasion. Recently, it has been reported that PD-L1 could play crucial roles in drug resistance of many kinds of
cancers. However, the expression, function, and regulation of PD-L1 in
sorafenib-resistant
hepatoma cells remain unclear. In this study, we reported that PD-L1 was overexpressed in
sorafenib-resistant
hepatoma cells, and
shRNA-mediated PD-L1 depletion attenuated drug resistance and suppressed the migration, invasion, colony formation, and
tumorigenesis in
sorafenib-resistant
hepatoma cells in vitro and in vivo. Mechanistic investigations indicated that loss of microRNA-1 (miR-1), a
tumor-suppressive
microRNA, contributed to the PD-L1 upregulation in
sorafenib-resistant
hepatoma cells, and PD-L1 was a direct regulatory target of miR-1. Further study revealed that an oncogenic transcriptional factor,
nuclear factor E2-related factor 2 (NRF-2), was induced in
sorafenib-resistant
hepatoma cells and inhibited expression of miR-1 in vitro. From molecular mechanism insight back to the functional verification, we eventually demonstrated that miR-1 executed its
tumor-suppressive effects on drug resistance and other malignant properties in
sorafenib-resistant
hepatoma cells partially by PD-L1 inhibition in vitro and in vivo. In conclusion, our data suggested that a NRF-2/miR-1/PD-L1 regulatory axis contributed to the development and maintenance of drug resistance and other tumorigenic properties in
sorafenib-resistant
hepatoma cells and provided a potential therapeutic target for overcoming
sorafenib resistance in HCC.